Flanagan W. Michael 4
4 · Avidity Biosciences, Inc. · Filed Sep 12, 2025
Insider Transaction Report
Form 4
Flanagan W. Michael
Chief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-09-11−20,000→ 76,500 totalExercise: $14.22Exp: 2032-01-20→ Common Stock (20,000 underlying) - Exercise/Conversion
Common Stock
2025-09-11$14.22/sh+20,000$284,400→ 100,195 total - Sale
Common Stock
2025-09-11$38.94/sh−20,000$778,702→ 80,195 total
Footnotes (3)
- [F1]The exercise and sales reported in this report were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person.
- [F2]This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.85 to $41.52. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 3, 2022 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date.